

Olmesartan Medoxomil Tablets

Type of Posting	Revision Bulletin
Posting Date	30-Jul-2021
Official Date	1-Aug-2021
Expert Committee	Small Molecules 2

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 2 Expert Committee has revised the Olmesartan Medoxomil Tablets monograph. The purpose of the revision is to add *Dissolution Test 8* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s).

- *Dissolution Test 8* was validated using the Symmetry C18 brand of column with L1 packing (4.6-mm × 25-cm; 5-μm). The typical retention time for olmesartan medoxomil is about 5 min.

Existing references to reagents also have been updated for consistency with the reagent entry names. For additional information about reagent cross-references, please see the related [Compendial Notice](#).

The Olmesartan Medoxomil Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Iffaaz Salahudeen, Senior Scientist II (609-902-5728 or Iffaaz.salahudeen@usp.org).